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Abstract: 
A fast headspace GC-MS method was developed and validated for the detection and 
quantification of residual solvents of all three ICH-classes in counterfeit tablets and capsules. 
The method was validated for ten solvents, selected based on an initial screening of 
counterfeit medicinal products. The considered solvents were ethanol, 2-propanol, acetone, 
ethylacetate, chloroform, carbon tetrachloride, benzene, toluene, dichloromethane and 
ethylbenzene. The proposed method uses a Phenomenex 624 capillary column (60 m x 0.32 
mm; 1.8 µm film thickness) (Phenomenex, Torrance, USA) with an oven temperature 
program from 60°C (held for 5 min) to 270°C at 25 °C/min. 270°C is held for 10 min. The 
total run time is 23.4 minutes.  
The obtained method was fully validated by applying the “total error” profile. Calibration 
lines for all components were linear within the studied ranges. The relative bias and the 
relative standard deviations for all components were smaller than 5%, the β-expectation 
tolerance limits did not exceed the acceptance limits of ±10% and the relative expanded 
uncertainties were acceptable for all of the considered components.   
A method was obtained for the screening and quantification of residual solvents in counterfeit 
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The analysis of residual solvents in pharmaceutical preparations is an important issue in the 
quality control of medicines, due to the potential risks for public health. In general the 
analysis of these solvents consists of a quantitative analysis using gas chromatography, which 
is used to check the adherence of the products to the limits for residual solvents imposed by 
the competent authorities. In 1997 the International Committee for Harmonisation issued a 
guideline for residual solvents [1]. The limits proposed in this guideline have been adopted by 
the United States Pharmacopoeia [2], the European Pharmacopoeia [3] and the Japanese 
Pharmacopoeia [4]. The guidelines divide the residual solvents into three classes. Class 1 
consists of solvents that should be avoided in pharmaceutical preparations due to their high 
toxicity, class 2 are the solvents that should be limited and class 3 consists of the solvents 
with a relatively low toxicity. Following the European Pharmacopoeia [3] the class 1 solvents 
(e.g. benzene, carbon tetrachloride,…) have limits between 2 and 8 ppm. 1,1,1-trichloroethane 
is also part of the class 1 solvents due to its environmental hazard. The limit here is up to 
1500 ppm. For the class 2 solvents (e.g. chloroform, methanol, hexane,…) the limits vary 
between 50 and 5000 ppm, while the class 3 solvents (e.g. acetic acid, ethanol, formic 
acid,…) are limited to 5000 ppm.   
The European Pharmacopoeia describes two gas chromatographic methods with static head-
space injection and a flame ionisation detector, which allow: the identification of class 1, 2 
and 3 solvents, to conduct a limit test and to quantify class 2, with limits higher than 1000 
ppm, and class 3 solvents if necessary. The European Pharmacopoeia also allows the use of a 
mass spectrometer and if needed an electron capture detector for chlorinated solvents of class 
1 [3].  
Due to the importance of the control of residual solvents in the quality of medicines several 
methods, applications and issues concerning residual solvents were already published and 
recently reviewed by Grodowska and Parczewski [5,6]. Despite the extended number of 
papers published in this domain, it is still an actual subject as is shown by some recent 
publications by the group of Adams and Van Schepdael [7-9].  
Residual solvents are also one of the concerns in the domain of counterfeit medicines. 
Counterfeit medicines are a growing threat for public health, both in developing as in 
industrial countries and this due to the extension of the internet [10,11]. The European 
Agency for Access to Safe Medicines (EAASM) claims that about 50% of the medicines sold 
through non identified/recognized websites are counterfeit and that 10% of the market in the 
developing countries and about 1% of the European market is covered by counterfeits [12]. In 
Europe and the United States the most popular groups of medicines bought through the 
internet are the phosphodiesterase type 5 (PDE-5) inhibitors and slimming products 
containing anorexics.  
The World Health Organization (WHO) [13] defines a counterfeit drug as: “one which is 
deliberately and fraudulently mislabelled with respect to identity and/or source. 
Counterfeiting can apply to both branded and generic products and counterfeit products may 
include products with the correct ingredients or with the wrong ingredients, without the active 
ingredients, with insufficient active ingredient or with fake packaging.”  
Health risks related to these products can be due to the absence of the active ingredient, the 
presence of a wrong active substance, a wrong dosage, possible high concentrations of toxic 
impurities and a combination of (non-approved) active substances. In general counterfeit 
medicines are evaluated based on an identification and quantification of the active substances 
and sometimes the determination of some degradation products [14-15]. Due to the fact that 
the majority of the counterfeit medicines are produced by street laboratories, without 
respecting the norms of Good Manufacturing Processes (GMP) or other quality norms, and 
using inferior primary substances, the impurities are more and more of interest for the 
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evaluation of counterfeit pharmaceutical preparations. For example a preparation can be 
considered relatively save based on the qualitative and quantitative analysis of the active 
substance, but can contain high concentrations of potential toxic impurities. One of the groups 
of impurities, which are of major concern, especially for products used chronically, are the 
residual solvents.  
This paper describes a gas chromatographic method that can be used to identify and quantify 
residual solvents in pharmaceutical preparations. The method uses a static headspace injector 
and a mass spectrometer as detection. The method was validated for a group of solvents 
encountered frequently in counterfeit medicines and over a wide range of concentrations. This 
due to the fact that it is to be expected that concentrations can be higher compared to 
regular/genuine pharmaceutical preparations. 
 
2. Methods and materials 
2.1. Chemicals and reagents 
2-propanol (HPLC grade), dichloromethane (HPLC grade) ethylacetate (pesti-S), acetone 
(HPLC-grade) ethanol absolute and acetonitril (HPLC grade) were purchased from Biosolve 
(Valkenswaard, The Netherlands). Chloroform (for gas chromatography), benzene, carbon 
tetrachloride (CCl4) (for spectroscopy) and ethylbenzene (for gas chromatography) were 
purchased from Merck (Darmstadt, Germany) and Toluene (pesticide residues) and 
cyclohexane from VWR prolabo (Fontenay-Sous-Bois, France). These solvents were used as 
reference standards. Dimethyl Sulfoxide, used as solvent for the samples was purchased from 
Merck. 
    
2.2. Instrumental conditions 
The samples were injected on a GC-MS system using a G188A headspace sampler (Agilent 
Technologies, Palo Alto, USA). The analyses were performed on an Agilent 6890N gas 
chromatograph coupled to an Agilent 5973N mass selective detector. Full automation was 
achieved using Agilent MSD ChemStation data acquisition and data handling software. After 
incubation of the sample (5 ml in a 10 ml headspace vial) at 120°C for 15 min, during which 
it was shaken, 0.5 ml of the vapour phase was injected into the GC/MS system in a split 
injection mode (split ration 6.8:1). The temperatures of the headspace loop, the transfer line 
and the EPC volatiles interface were 135, 145 and 160°C respectively. The solvents were 
separated on a Phenomenex 624 capillary column (60 m x 0.32 mm; 1.8 µm film thickness) 
(Phenomenex, Torrance, USA). The oven temperature was programmed from 60°C (held for 
5 min) to 270°C at 25 °C/min. 270°C is held for 10 min. The total run time is 23.4 minutes. 
The temperatures of the injection port, the ion source, the quadrupole and the interface were 
set at 160, 230, 150 and 280°C, respectively. For the identification of the solvents present in 
the samples the mass spectrometer was operated in full scan mode. For quantification and 
validation the mass spectrometer was operated in SIM mode (100 ms dwell times). Table 1 
presents the specific m/z ratios monitored for each of the selected solvents as well as their 
retention times and the group start times (opening window) for the SIM mode. For 










Table1: specific m/z ratios and retention times for the selected solvents 
 
Solvent Specific m/z ratios Group start times 
(min) 
Retention times (min) 
Ethanol 45.0 - 5.14 
2-propanol 41.0, 43.0, 45.0, 49.0 5.50 5.81 
Acetone 41.0, 43.0, 45.0, 49.0 5.50 5.73 
Dichloromethane 49.0 5.50 6.33 
Ethylacetate 43.1 7.65 7.81 
Chloroform 82.9 8.10 8.20 
Carbon tetrachloride 56.1, 116.9 8.32 8.63 
Benzene 78.1 8.75 8.87 
Toluene 91.1 10.70 10.86 
Ethylbenzene 106.0 12.20 12.30 
 
2.3. Sample preparations 
2.3.1. Preparation of internal standard solution 
A stock solution containing 1000 ppm of acetonitril and cyclohexane in dimethylsulfoxide 
was prepared separately. 1 ml was diluted to 100,0 ml dimethylsulfoxide and used as internal 
standard. Cyclohexane was used for the quantification of CCl4, benzene, toluene and 
ethylbenzene, while acetonitril was used as internal standard for the remaining solvents. The 
selection of the internal standards was based on an initial screening of counterfeit samples. 
Both internal standards were not detected or only as traces. 
 
2.3.2. Preparation of standards 
One stock solution was prepared containing 1000 ppm of all the selected solvents, besides 
acetonitril and cyclohexane, in dimethyl sulfoxide. Starting from the stock solutions, dilutions 
were prepared in the same solvent to obtain standards containing 10, 1 and 0.5 ppm of each 
solvent. 500 µl of the internal standard solution was added to 5 ml of the standard solutions to 
obtain concentrations of internal standard of about 1 ppm. The solutions were brought in vials 
and electronically sealed. Dimethyl sulfoxide was used as blank. The choice of the solvent 
was based on a preliminary screening of about 150 samples in which dimethyl sulfoxide could 
not be detected. Therefore it was assumed that dimethyl sulfoxide is not present in the 
samples. 
 
2.3.3. Preparation of samples 
In order to validate the method following, the “total error” approach, blank spiked samples 
were prepared starting from a stock solution with the same concentrations as the one used for 
the preparation of the standards. As blank matrix, lactose monohydrate was used, since it is 
the most used excipient in counterfeit samples of PDE-5 inhibitors and slimming products, the 
two main groups of counterfeit medicines seized in Belgium. A stock solution for sample 
preparation, containing 1000 ppm of each solvent, was prepared separately from the one used 
for the standards. Starting from this stock solution, three samples were prepared with different 
concentration levels. The selected levels were 0.5, 1 and 10 ppm of each of the selected 
solvents. Also here 500 µl of the internal standard solution was added to 5 ml of the sample 
solution. The solutions were brought in vials and electronically sealed. 
For the analysis of tablets, the tablets were broken in two before addition of 5 ml of 
dimethylsulfoxide. Tablets were broken because of the coating of some of the tablets, 
possibly preventing the recovery of the residual solvents. To this solution 500 µl of the 
internal standard solution was added.  Capsules were opened before addition of the solvent. 
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2.4. Method validation 
The method validation was performed in accordance with the requirements of the ISO17025 
guideline using the total error approach [16-19].  
 
2.5. Statistics 
The statistical analysis was performed using Microsoft Excel 2003.  
 
3. Results 
The method as described in section 2.2 was applied to standards and samples. Figure 1 shows 
the chromatogram as obtained for a standard solution containing the ten selected solvents for 
validation and the two internal standards. The chromatogram was recorded in full scan mode. 
Figure 2 gives an example of a chromatogram obtained for a genuine sample compared to the 
one obtained for a corresponding counterfeit sample. As example a genuine and a counterfeit 
tablet of Viagra® was used. Both chromatograms were recorded in full scan mode. The 
chromatograms show a clear difference in the amounts of residual solvent difference and so in 
the risk they can represent to public health. The presence of 2-butanone in both genuine as 





Figure 1: Chromatogram of a standard solution containing all the selected solvents. The chromatogram was 




Figure 2: Chromatograms obtained for a genuine and a counterfeit samples in full scan mode. 
 
3.1. Selectivity 
The selectivity of the detection was ensured by monitoring the specific ions of the residual 
solvent in selective ion monitoring (SIM) mode of the mass spectrometer. 
 
3.2. Linearity of the calibration line 
For all ten solvents three calibration standards were prepared in order to evaluate the 
relationship between the area under the curve and the concentration. The linearity of the 
relationship was evaluated for each of the components in a concentration range of 0.5 to 10 
ppm, covering the range in which residual solvent analysis is usually performed.  
The calibration curves were obtained using ordinary least-square linear regression and the 
linearity was confirmed with the R² values and a quality coefficient [20]. Table 2 summarizes 
for the twelve solvents the R² values and the quality coefficients. For all curves the g values 
were below 0.01 [21]. From this table it can clearly been concluded that the calibration curves 
for all components are linear within the chosen concentration ranges.  
 
3.3. Trueness, precision, accuracy and uncertainty assessment 
A statistical approach based on the “total error” profiles was applied to validate the method. 
As explained in section 2.3.2 spiked blank samples were prepared at three concentration 
levels. For the different solvents the blank sample (lactose) was spiked with amounts of 
solvent resulting in concentrations of respectively 0.5, 1 and 10 ppm.  Every sample was 
prepared in triple and analysed for three consecutive days.  
The concentrations of the spiked samples were back-calculated using the calibration lines, 
prepared as described in section 2.3.1., to determine the linearity between theoretical and 
measured concentrations, the mean relative bias, the repeatability, the intermediate precision, 
the β-expectation tolerance or total error intervals at the 5% level and the measurement 
uncertainty. All results are shown in table 3. 
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Table 2: summary of the quality of the calibration curves for the different solvents 
 
Component R² value Quality 
Coefficient (%) 
Ethanol 0.9999 4.89 
2-propanol 0.9962 4.19 
Acetone 0.9983 1.40 
Ethylacetate 0.9998 0.379 




Benzene 0.9996 4.05 
Toluene 0.9990 4.94 
Dichloromethane 0.9996 1.45 
Ethylbenzene 0.9995 4.02 
 
The relationship between the theoretical and the calculated concentrations for each of the ten 
solvents is clearly linear with R²-values from 0.9994 to 1.000. 
Trueness (ISO definition) refers to the closeness of agreement between the average of the 
obtained values and the known exact concentration of the spiked samples and is a measure for 
the systematic errors of the method [19]. It is expressed in terms of relative bias.  From table 3 
it can be concluded that the trueness for all components is acceptable since the relative bias is 
always smaller than 5%. Five percent is accepted, since we are working with GC-MS, which 
is a semi quantitative method.  
The precision is a measure for the relative errors of the method and is expressed as the relative 
standard deviations (RSD) for repeatability and intermediate precision. From table 3 it can be 
seen that an acceptable precision is obtained for all solvents. The maximal RSD is obtained 
for the intermediate precision for dichloromethane and is 3.62%.  
Accuracy takes into account the total error of the test results and is represented by the β-
expectation tolerance intervals. The acceptance limits for the bias were set at ±10 %. As 
shown in table 3 and figure 3 the relative β-expectation tolerance intervals did not exceed the 
acceptance limits, except for the lowest level of ethanol (0.5 ppm). Since ethanol is a class 3 
solvent and the fact that concentrations can be augmented for quantification when ethanol is 
detected, this is not considered a problem. This means that each future measurement of 
unknown samples will be included in the tolerance limits for the relative bias at the 10% 
level.  
The uncertainty represents the dispersion of the values that could reasonably be attributed to 
the analyte. The expanded uncertainty represents an interval around the results where the 
unknown true value can be observed with a confidence level of 95%. The relative expanded 
uncertainties (%) are obtained by dividing the corresponding expanded uncertainties with the 





Table 3: Trueness, precision, accuracy and uncertainty 
 
Level Ethanol 2-propanol aceton ethylacetate chloroform 
Carbon 




          
 
 1 -1,71 1,31 -1,64 -3,06 -2,38 0,21 -0,73 -2,14 -4,75 -2,57 
Relative bias (%) 2 -1,49 0,55 0,69 1,04 0,56 -0,23 1,11 -0,09 1,07 0.58 
 3 0,01 0,00 -0,01 -0,02 -0,01 0,00 0,01 -0,02 -0,03 -0,02 
Intra-assay precision 
           
 1 0,90 2,39 2,18 2,15 1,43 0,95 1,00 1,25 3,56 1,76 
Repeatability (RSD %) 2 2,93 1,84 1.10 1,06 2,06 1,55 1,85 2,15 1,30 2,21 
 3 2,49 2,25 2,65 2,32 1,59 1,51 1,48 1,53 2,34 1,73 
Between-assay 
precision 
           
 1 2,44 2,64 2,24 2,44 2,03 1,35 1,42 2,31 3,62 2,54 
Intermediate precision 
(RSD %) 2 3,45 1,84 1,47 1,06 2,06 1,55 1,85 2,21 1,75 2,21 
 3 2,49 2,25 2,65 2,32 1,59 1,51 1,48 1,53 2,34 1,73 
Accuracy 
           
 1 [-10,18;-6,76] [-7,52;4,91] [-6,77;3,49] [-8,84;2,72] [-7,62;2,86] [-3,38;3,79] [-4,44;2,98] [-9,03;4,76] [-9,12;6,34] [-9,12;3,93] 
β-expectation tolerance 
limits (%) 2 [-9,87;6,88] [-3,74;4,85] [-3,20;4,58] [-1,45;3,52] [-4,26;5,37] [-3,82;3,35] [-3,23;5,45] [-5,24;5,06] [-4,34;6,48] [-4,58;5,74] 
 3 [-5,77;5,80] [-5,23;5,22] [-6,15;6,13] [-5,40;5,37] [-3,69;3,68] [-3,51;3,50] [-3,41;3,43] [-3,56;3,52] [-5,86;5,80] [-4,03;3,99] 
Uncertainty 
           
 1 5,32 5,49 4,60 5,02 4,28 2,93 3,03 4,96 6,02 5,35 
Relative expanded 
uncertainty (%) 2 7,26 3,86 3,18 2,23 4,32 3,22 3,90 4,62 3,90 4,64 












































































































































































































Figure 3: Accuracy profile of ten solvents. The plain line is the relative bias, the dashed lines are the β-
expectation tolerance limits, the bold plain line are the acceptance limits (10%) and the dots represent the 
relative back-calculated concentrations, plotted with respect to their targeted concentration. 
 
3.4. Limits of detection and quantification (LOD AND LOQ) 
The LOD and LOQ were determined using the signal to noise ration (S/N) method. This 
approach consists in measuring the peak-to-peak noise around the retention time of the 
considered analyte, followed by an estimation of the concentration of the analyte that would 
result in a predetermined value for S/N. In general an S/N value of 3 is accepted for the 
estimation of the LOD and an S/N value of 6 for the LOQ. In practise blank samples, spiked 
with decreasing amounts of the analyte are analysed. The lowest concentrations fulfilling the 
S/N criteria are the LOD and LOQ. Table 4 gives an overview of the estimated LOD/LOQ for 
each of the considered solvents. The LOD was determined using the screening method (the 




The absolute recoveries of the ten solvents were determined at the three concentration levels 
used to construct the accuracy profile. The recoveries were determined by analysing spiked 
blank samples and calculating their concentrations using calibration lines in analogy with 
what was done for the accuracy profile. The mean recoveries for all ten solvents considered in 
the validation are ranging from 99.2 to 100.5 %.  The recoveries are within the limits of 98.5 
and 101.5%, indicating that the method is suited for the analysis of the considered residual 




Table 4: Estimated values for LOD (TIC-mode, screening) and LOQ (SIM-mode, quantification) for the 
different solvents 
Component LOD (ppm) LOQ (ppm) 
Ethanol 8.125 0.114 
2-propanol 0.360 0.001 
Acetone 0.377 0.001 
Ethylacetate 0.421 0.421 
Chloroform 0.589 0.002 
Carbon tetrachloride 0.414 0.001 
Benzene 0.453 0.001 
Toluene 0.552 0.002 
Dichloromethane 0.589 0.002 
Ethylbenzene 0.478 0.002 
 
 
4. Conclusions  
A fast approach for the screening and the quantification of residual solvents in counterfeit 
tablets and capsules was developed and validated. The validation was performed following 
the ISO17025 requirements and proved that the method was suited for purpose and can be 
used in the routine analysis of these pharmaceutical preparations. For the validation a set of 
ten residual solvents was selected, based on an initial screening of a set of counterfeit 
samples. Nevertheless the method is suited for the detection and quantification of all residual 
solvent described in the European Pharmacopoeia [3], since the ten selected solvents cover 
the whole range of the chromatogram. 
The method uses a Phenomenex 624 capillary column (60 m x 0.32 mm; 1.8 µm film 
thickness) (Phenomenex, Torrance, USA) and an oven program starting from 60°C (held for 5 
min) to 270°C at 25 °C/min. 270°C is held for 10 min.  The temperatures of the injection port, 
the ion source, the quadrupole and the interface were set at 160, 230, 150 and 280°C, 
respectively.  
The method was applied in the analysis of routine samples at our lab and showed a good 
overall performance. Just as example table 5 shows the results obtained for a few tablets of 
professional and non-professional imitations of Viagra® analysed at our lab. The table 
represents only the selected solvents in this study, since the selection was based on this group 
of counterfeits (Viagra®). It is clear that the screening and quantification method can also be 
applied for other residual solvents found in other groups of counterfeited medicines. 
The method can be used in the risk evaluation of counterfeit tablets and capsules concerning 
the public health. Nowadays the risk evaluation of counterfeit medicines is mainly based on 
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the identification and the quantification of the active substances and sometimes the presence 
of analogs and degradation products. We are strongly convinced that in the future the 
governmental institution should turn to a more complete risk evaluation of counterfeit 
samples where, besides the active ingredients also secondary ingredients should be taken into 
account, like impurities originating from the manufacturing process. Residual solvent 
screening fits in this idea, since high levels of residual solvents can be considered an 
important threat to public health. 
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Table 5: residual solvent content for 10 professional en non professional imitations of Viagra® (sildenafil) tablets analysed with the proposed method. (“-“ indicates an amount 






















1 - 184.9 20.5 - - - - - - - 
2 - 1112.7 7.7 - - - - - - - 
3 - 333.7 4.9 - - - - - 3.2 - 
4 - 301.7 16.1 - - - - - 6.8 - 
5 - 23.2 217.0 - - - - - - - 
6 - 563.8 22.3 - - - - - 5.9 - 
7 858.6 22.9 0.7 10.6 - - - - - - 
8 25.5 4.8 7.4 - - 7.8 - - - - 
9 27.4 116.5 63.8 - - 47.0 - - - - 
10 - 140.6 5.3 - - - - - - - 
 14
References 
[1] International Conference on Harmonisation (ICH) of Technical Requirements for the 
Registration of Pharmaceuticals for Human Use, Q3C: impurities: Guidelines for Residual 
Solvents, Step 4 (1997) 
[2] United States Pharmacopoeia 35, United States Pharmacopeial Convention, Inc., 
Rockville, MD, USA (2010) 
[3] European Pharmacopoeia 7.0 (2010), Council of Europe, Strasbourg, France 
[4] Japanese Pharmacopoeia, 16th ed., Society of Japanese Pharmacopoeia, Tokyo (2011) 
[5] K. Grodowska, A. Parczewski, Organic solvents in the pharmaceutical industry, Acta Pol. 
Pharm. 67 (2010), 3-12 
[6] K. Grodowska, A. Parczewski, Analytical methods for residual solvents determination in 
pharmaceutical products, Acta Pol Pharm. 67 (2010), 13-26 
[7] W. D'Autry, C. Zheng, K. Wolfs, S. Yarramraju, J. Hoogmartens, A. Van Schepdael, E. 
Adams, Mixed aqueous solutions as dilution media in the determination of residual solvents 
by static headspace gas chromatography, J. Sep Sci. 34 (2011),1299-1308 
[8] W. D'Autry, C. Zheng, J. Bugalama, K. Wolfs, J. Hoogmartens, E. Adams, B. Wang, A. 
Van Schepdael, Liquid paraffin as new dilution medium for the analysis of high boiling point 
residual solvents with static headspace-gas chromatography, J. Pharm. Biomed. Anal. 55 
(2011), 1017-1023. 
[9] W. D'Autry, K. Wolfs, J. Hoogmartens, E. Adams, A. Van Schepdael, Improving 
quantitative gas chromatography-electron ionization mass spectrometry results using a 
modified ion source: demonstration for a pharmaceutical application, J. Chromatogr. A 18 
(2011), 4034-4038. 
[10] A. Weiss, Buying prescription drugs on the internet: promises and pitfalls, Cleve. Clin. J.  
Med. 73 (2006), 282-288. 
[11] M. Veronin, B.-B. Youan, Magic bullet gone astray: medications and the internet, 
Science 305 (2004) 481. 
[12] European Alliance For Acces to Safe Medicines: www.eaasm.eu  
[13] WHO, sixty-second world health assembly item 12.9, counterfeit medical products, april 
2009. http://aps.who.int/gb/ebhwa/pdf_files/A62/A62_13-en.pdf 
[14] P.Y. Sacré, E. Deconinck, P. Chiap, J. Crommen, E. Rozet, P. Courselle, J. O. De Beer, 
Development and validation of a UHPLC-UV method for the detection and quantification of 
erectile dysfunction drugs and some of their analogues found in counterfeit medicines, J. 
Chromatogr. A 1218 (2011) 6439-6447. 
[15] E. Deconinck, K. Verlinde, P. Courselle, J. De Beer, A validated Ultra High Pressure 
Liquid Chromatographic method for the characterisation of confiscated illegal slimming 
products containing anorexics, J. Pharm.Biomed. anal. 59 (2012) 38-43. 
[16] EN ISO/IEC 17025 (2005) General requirements for the competence of testing and 
calibration laboratories (www.iso.org)  
[17] M. Fienberg, Validation of analytical methods based on accuracy profiles, J. 
Chromatogr. A 1158 (2007), 174-183. 
[18] M. Feinberg, M. Laurentie, A global approach to method validation and measurement 
uncertainty, Accred Qual Assur 11(2006), 3-9. 
[19] B. De Backer, B. Debrus, P. Lebrun, L. Theunis, N. Dubois, L. Decock, A. Verstraete, P. 
Hubert, C. Charlier, Innovative development and validation of an HPLC/DAD method for the 
qualitative and quantitative determination of major cannabinoids in cannabis plant material, J. 
chromatogr. B  877 (2009), 4115-4124.  
 
 15
[20] J.O. De Beer, T.R. De Beer, L. Goeyens, Assessment of quality performance parameters 
for straight line calibration curves related to the spread of the abscissa values around their 
mean, Anal Chim Acta.  584 (2007) 57-65 
[21] J.O. De Beer, C. Naert, E. Deconinck, the quality coefficient as performance assessment 
parameter of straight line calibration curves in relationship with the number of calibration 
points., Accred. Qual. Assur. In press, DOI: 10.1007/s00769-011-0871-1 
 
